BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln

Reuters

Feb 26

Feb 26 (Reuters) - Novavax Inc NVAX.O:

NOVAVAX OUTLOOK 2026 ADJUSTED TOTAL REVENUE $230 MILLION - $270 MILLION
NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&A EXPENSES NOW TARGETED TO BE $325 MILLION AND $225 MILLION FOR 2026 AND 2027, RESPECTIVELY
NOVAVAX Q4 EPS $0.11
NOVAVAX Q4 TOTAL REVENUE $147.1 MILLION
FY2026 REVENUE VIEW $377.0 MILLION -- LSEG IBES DATA
Q4 EARNINGS PER SHARE VIEW $-0.49, REVENUE VIEW $78.8 MILLION -- LSEG IBES DATA
NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&A EXPENSES FOR 2028 TARGETED TO BE AT $200 MILLION OR BELOW

Further company coverage: NVAX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614449260"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614449260\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614449260?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614449260","market":"nz","top_or_hot":-1,"title":"BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln</title></head><body><p><span>Feb 26 (Reuters)</span><span> - </span>Novavax Inc <span>NVAX.O</span>:</p><ul><li><p>NOVAVAX OUTLOOK 2026 ADJUSTED TOTAL REVENUE $230 MILLION - $270 MILLION</p></li><li><p>NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&amp;A EXPENSES NOW TARGETED TO BE $325 MILLION AND $225 MILLION FOR 2026 AND 2027, RESPECTIVELY</p></li><li><p>NOVAVAX Q4 EPS $0.11</p></li><li><p>NOVAVAX Q4 TOTAL REVENUE $147.1 MILLION</p></li><li><p>FY2026 REVENUE VIEW $377.0 MILLION -- LSEG IBES DATA</p></li><li><p>Q4 EARNINGS PER SHARE VIEW $-0.49, REVENUE VIEW $78.8 MILLION -- LSEG IBES DATA</p></li><li><p>NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&amp;A EXPENSES FOR 2028 TARGETED TO BE AT $200 MILLION OR BELOW</p></li></ul><p>Further company coverage: <span>NVAX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 Mln</title></head><body><p><span>Feb 26 (Reuters)</span><span> - </span>Novavax Inc <span>NVAX.O</span>:</p><ul><li><p>NOVAVAX OUTLOOK 2026 ADJUSTED TOTAL REVENUE $230 MILLION - $270 MILLION</p></li><li><p>NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&amp;A EXPENSES NOW TARGETED TO BE $325 MILLION AND $225 MILLION FOR 2026 AND 2027, RESPECTIVELY</p></li><li><p>NOVAVAX Q4 EPS $0.11</p></li><li><p>NOVAVAX Q4 TOTAL REVENUE $147.1 MILLION</p></li><li><p>FY2026 REVENUE VIEW $377.0 MILLION -- LSEG IBES DATA</p></li><li><p>Q4 EARNINGS PER SHARE VIEW $-0.49, REVENUE VIEW $78.8 MILLION -- LSEG IBES DATA</p></li><li><p>NOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&amp;A EXPENSES FOR 2028 TARGETED TO BE AT $200 MILLION OR BELOW</p></li></ul><p>Further company coverage: <span>NVAX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nP8N3W407C:1","article_id":"2614449260","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614449260","pubTimestamp":1772110811,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 MlnFeb 26 (Reuters) - Novavax Inc NVAX.O:NOVAVAX OUTLOOK 2026 ADJUSTED TOTAL REVENUE $230 MILLION - $270 MILLIONNOVAVAX: ADJUSTED FY R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4547":"WSB热门概念","NVAX":"诺瓦瓦克斯医药","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"简报-Novavax展望2026年调整后总收入为2.3亿美元至2.7亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"BRIEF-Novavax Outlook 2026 Adjusted Total Revenue $230 Mln - $270 MlnFeb 26 (Reuters) - Novavax Inc NVAX.O:NOVAVAX OUTLOOK 2026 ADJUSTED TOTAL REVENUE $230 MILLION - $270 MILLIONNOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&A EXPENSES NOW TARGETED TO BE $325 MILLION AND $225 MILLION FOR 2026 AND 2027, RESPECTIVELYNOVAVAX Q4 EPS $0.11NOVAVAX Q4 TOTAL REVENUE $147.1 MILLIONFY2026 REVENUE VIEW $377.0 MILLION -- LSEG IBES DATAQ4 EARNINGS PER SHARE VIEW $-0.49, REVENUE VIEW $78.8 MILLION -- LSEG IBES DATANOVAVAX: ADJUSTED FY RESEARCH AND DEVELOPMENT AND SG&A EXPENSES FOR 2028 TARGETED TO BE AT $200 MILLION OR BELOWFurther company coverage: NVAX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}